Selected Articles from This Issue
Journal: Clinical Cancer Research (2023)

Highlights| April 14 2023 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2023 American Association for Cancer Research2023American Association for Cancer Research Clin Cancer Res (2023) 29 (8): 1375. https://doi.org/10.1158/1078-0432.CCR-29-8-HI Related Content A commentary has been published: [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study A commentary has been published: The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial A commentary has been published: Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance View more A commentary has been published: A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid) View less See also commentary [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid) Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record April 14 2023 Citation Selected Articles from This Issue. Clin Cancer Res 15 April 2023; 29 (8): 1375. https://doi.org/10.1158/1078-0432.CCR-29-8-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Pharmacologic inhibition of the δ isoform of phosphatidylinositol 3-kinase (PI3Kδ) reduces proliferation, migration, and survival of the malignant B-cell leukemia and lymphoma cells. The novel orally active PI3Kδ inhibitor linperlisib has shown a notable efficacy in B-cell lymphomas, especially for a FL subgroup, in a previous phase I study. In this phase II trial, Wang and colleagues report that linperlisib demonstrated compelling efficacy and was generally well tolerated in the treatment of relapsed or refractory FL patients after two or more prior systemic therapies. Enfortumab vedotin (EV) releases a cytotoxic agent into the urothelial cancer (UC) cell via binding to the surface protein NECTIN-4. Although EV is approved in the metastatic disease stage, the NECTIN-4 expression in metastatic UC tissue is insufficiently studied. Here, Klümper and colleagues demonstrate that NECTIN-4 expression decreases substantially during metastatic evolution and is absent in more than one-third of metastases. Further, loss of membranous NECTIN-4... You do not currently have access to this content.